Table. Summary of other efficacy results[a]

	Lorlatinib	Crizotinib
ITT population	**(n=149)**	**(n=147)**
% alive without progression at: 12 mo (95% CI)	78 (70–84)	38 (29–47)
24	68 (60–75)	22 (14–30)
36	64 (55–71)	19 (12–27)
Median PFS by investigator, mo (95% CI)[a]	NR (NR–NR)	9.1 (7.4–10.9)
HR (95% CI)	0.19 (0.13–0.27)	
Confirmed OR by BICR, n (%) [95% CI]	115 (77) [70–84]	86 (59) [50–67]
Median DR,[b] mo (95% CI)	NR (NR–NR)	9.6 (9.0–12.9)
Patients with measurable or nonmeasurable brain metastases at baseline	**(n=37)**	**(n=39)**
Median PFS, mo (95% CI)	NR (18.2–NR)	7.2 (3.7–9.2)
HR (95% CI)	0.21 (0.10–0.44)	
Confirmed IC-OR, n (%) [95% CI]	24 (65) [48–80]	7 (18) [8–34]
Complete response, n (%)	22 (60)	5 (13)
Median IC-DR,[b] mo (95% CI)	NR (NR–NR)	9.4 (6.0–11.1)
Patients without measurable or nonmeasurable brain metastases at baseline	**(n=112)**	**(n=108)**
Median PFS, mo (95% CI)	NR (NR–NR)	11.0 (9.0–14.6)
HR (95% CI)	0.29 (0.19–0.44)	

[a]By BICR unless stated otherwise. [b]In patients with a confirmed complete or partial response. BICR, blinded independent central review; CI, confidence interval; DR, duration of response; HR, hazard ratio; ITT, intention-to-treat; NR, not reached; IC, intracranial; OR, objective response; PFS, progression-free survival.